

# New Hampshire Medicaid Fee-for-Service Program Hemgenix® (etranacogene dezaparvovec-drlb) Criteria

Approval Date: June 29, 2023

## Medications

Brand Names	Generic Names	Indication
Hemgenix®	etranacogene dezaparvovec-drlb	indicated for treatment of adults with hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage or repeated, serious spontaneous bleeding episodes

## Criteria for Approval

1. Patient is at least 18 years of age; **AND**
2. Prescribed by a hematologist and patient is managed by a hemophilia treatment center; **AND**
3. Patient has a diagnosis of moderately severe or severe congenital factor IX deficiency (e.g., factor IX  $\leq$  2%), as confirmed by blood coagulation testing; **AND**
4. Patient has one or more of the following:
  - a. Currently uses factor IX prophylaxis therapy; **OR**
  - b. Current or historical life-threatening hemorrhage; **OR**
  - c. Repeated, serious spontaneous bleeding episodes; **AND**
5. Patient has been tested and found negative for factor IX inhibitor titers (if test result positive, re-test within approximately 2 weeks. If re-test is also positive, Hemgenix® should not be given); **AND**
6. Patient factor IX (FIX) activity will be monitored periodically (e.g., weekly for 3 months); **AND**
7. Provider will monitor for presence of inhibitors if bleeding is not controlled (note: patient will continue to require exogenous factor IX until response to Hemgenix® occurs); **AND**
8. Patient will receive baseline liver function assessed prior to and after therapy weekly for at least 3 months; **AND**
9. Patients with preexisting risk factors for hepatocellular carcinoma (e.g., cirrhosis, advanced hepatic fibrosis, hepatitis C or B, non-alcoholic fatty liver disease [NAFLD], chronic alcohol consumption, non-alcoholic steatohepatitis [NASH], advanced age) will have abdominal ultrasound screenings and be monitored regularly (e.g., annually) for alpha-fetoprotein (AFP) elevations for 5 years following administration.

# Limitation

A single dose per lifetime.

# Criteria for Denial

- 1. Criteria for approval are not met.

# Revision History

Reviewed by	Reason for Review	Date Approved
DUR Board	New	06/19/2023
Commissioner Designee	Approval	06/29/2023